Reported Earnings • May 18
Full year 2026 earnings released: ₹1.68 loss per share (vs ₹0.14 profit in FY 2025) Full year 2026 results: ₹1.68 loss per share (down from ₹0.14 profit in FY 2025). Revenue: ₹13.8b (up 7.1% from FY 2025). Net loss: ₹74.1m (down ₹79.5m from profit in FY 2025). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. New Risk • May 15
New major risk - Revenue and earnings growth Earnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Aankondiging • May 08
Solara Active Pharma Sciences Limited to Report Q4, 2026 Results on May 15, 2026 Solara Active Pharma Sciences Limited announced that they will report Q4, 2026 results on May 15, 2026 Buy Or Sell Opportunity • Mar 27
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 21% to ₹443. The fair value is estimated to be ₹567, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.9% over the last 3 years. Earnings per share has grown by 6.5%. Buy Or Sell Opportunity • Mar 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 26% to ₹450. The fair value is estimated to be ₹566, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.9% over the last 3 years. Earnings per share has grown by 6.5%. Reported Earnings • Feb 07
Third quarter 2026 earnings released: ₹3.98 loss per share (vs ₹2.03 profit in 3Q 2025) Third quarter 2026 results: ₹3.98 loss per share (down from ₹2.03 profit in 3Q 2025). Revenue: ₹3.49b (up 16% from 3Q 2025). Net loss: ₹174.3m (down 316% from profit in 3Q 2025). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 7% per year and the company’s share price has also increased by 7% per year. Aankondiging • Jan 30
Solara Active Pharma Sciences Limited to Report Q3, 2026 Results on Feb 06, 2026 Solara Active Pharma Sciences Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Feb 06, 2026 Buy Or Sell Opportunity • Jan 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.8% to ₹576. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year. Buy Or Sell Opportunity • Dec 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to ₹573. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year. Buy Or Sell Opportunity • Nov 06
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.3% to ₹563. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year. Aankondiging • Oct 29
Solara Active Pharma Sciences Limited to Report Q2, 2026 Results on Nov 05, 2025 Solara Active Pharma Sciences Limited announced that they will report Q2, 2026 results on Nov 05, 2025 Aankondiging • Sep 02
Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 25, 2025 Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 25, 2025, at 10:30 Indian Standard Time. Reported Earnings • Jul 26
First quarter 2026 earnings released: EPS: ₹2.46 (vs ₹3.50 loss in 1Q 2025) First quarter 2026 results: EPS: ₹2.46 (up from ₹3.50 loss in 1Q 2025). Revenue: ₹3.19b (down 12% from 1Q 2025). Net income: ₹105.2m (up ₹239.8m from 1Q 2025). Profit margin: 3.3% (up from net loss in 1Q 2025). The move to profitability was driven by lower expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Aankondiging • Jul 18
Solara Active Pharma Sciences Limited to Report Q1, 2026 Results on Jul 25, 2025 Solara Active Pharma Sciences Limited announced that they will report Q1, 2026 results on Jul 25, 2025 New Risk • Jun 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). Board Change • May 21
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO & MD Sandeep Rao was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Aankondiging • May 10
Solara Active Pharma Sciences Limited to Report Q4, 2025 Results on May 15, 2025 Solara Active Pharma Sciences Limited announced that they will report Q4, 2025 results on May 15, 2025 Aankondiging • Feb 23
Solara Active Pharma Sciences Limited Announces Resignation of Poorvank Purohit as CEO Solara Active Pharma Sciences Limited at the Board of Directors meeting held on February 21, 2025 Mr. Poorvank Purohit tendered his resignation as the CEO of the Company, with effect from February 21, 2025, citing personal reasons. Reported Earnings • Jan 25
Third quarter 2025 earnings released: EPS: ₹2.03 (vs ₹76.34 loss in 3Q 2024) Third quarter 2025 results: EPS: ₹2.03 (up from ₹76.34 loss in 3Q 2024). Revenue: ₹3.02b (up 21% from 3Q 2024). Net income: ₹80.9m (up ₹2.83b from 3Q 2024). Profit margin: 2.7% (up from net loss in 3Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Aankondiging • Jan 25
Solara Active Pharma Sciences Limited Revises Earnings Guidance for the Year 2025 Solara Active Pharma Sciences Limited revised earnings guidance for the year 2025. The company will not get to the INR 14,000 million - INR 15,000 million range. The company will be more in the INR 13,000 million - INR 14,000 million range, which means that there is a drop in approximately INR 1,000 million of revenue. Aankondiging • Jan 16
Solara Active Pharma Sciences Limited to Report Q3, 2025 Results on Jan 24, 2025 Solara Active Pharma Sciences Limited announced that they will report Q3, 2025 results on Jan 24, 2025 New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 24
Second quarter 2025 earnings released: EPS: ₹2.54 (vs ₹4.77 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹2.54 (up from ₹4.77 loss in 2Q 2024). Revenue: ₹3.47b (down 18% from 2Q 2024). Net income: ₹80.1m (up ₹251.7m from 2Q 2024). Profit margin: 2.3% (up from net loss in 2Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Aankondiging • Oct 14
Solara Active Pharma Sciences Limited to Report Q2, 2025 Results on Oct 21, 2024 Solara Active Pharma Sciences Limited announced that they will report Q2, 2025 results on Oct 21, 2024 Recent Insider Transactions • Sep 29
Independent Chairman recently bought ₹2.4m worth of stock On the 26th of September, Ramakrishnan Rajagopal bought around 3k shares on-market at roughly ₹808 per share. This transaction increased Ramakrishnan's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ramakrishnan's only on-market trade for the last 12 months. Aankondiging • Aug 28
Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 20, 2024 Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 20, 2024, at 10:00 Indian Standard Time. Price Target Changed • Jul 23
Price target increased by 40% to ₹485 Up from ₹347, the current price target is provided by 1 analyst. New target price is 20% below last closing price of ₹604. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹8.30 next year compared to a net loss per share of ₹158 last year. Reported Earnings • Jul 23
First quarter 2025 earnings released: ₹3.50 loss per share (vs ₹5.43 loss in 1Q 2024) First quarter 2025 results: ₹3.50 loss per share (improved from ₹5.43 loss in 1Q 2024). Revenue: ₹3.63b (up 3.2% from 1Q 2024). Net loss: ₹134.6m (loss narrowed 31% from 1Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance. Aankondiging • Jul 16
Solara Active Pharma Sciences Limited to Report Q1, 2025 Results on Jul 22, 2024 Solara Active Pharma Sciences Limited announced that they will report Q1, 2025 results on Jul 22, 2024 Price Target Changed • Jun 20
Price target increased by 9.7% to ₹381 Up from ₹347, the current price target is an average from 2 analysts. New target price is 15% below last closing price of ₹448. Stock is up 22% over the past year. The company is forecast to post earnings per share of ₹8.70 next year compared to a net loss per share of ₹158 last year. Buy Or Sell Opportunity • Jun 06
Now 25% overvalued Over the last 90 days, the stock has fallen 1.0% to ₹425. The fair value is estimated to be ₹339, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 12% in a year. Earnings are forecast to grow by 84% in the next year. New Risk • May 24
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risk Shareholders have been diluted in the past year (33% increase in shares outstanding). Aankondiging • May 23
Solara Active Pharma Sciences Limited to Report Q4, 2024 Results on May 29, 2024 Solara Active Pharma Sciences Limited announced that they will report Q4, 2024 results on May 29, 2024 Buy Or Sell Opportunity • May 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 38% to ₹554. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 16% in a year. Earnings are forecast to grow by 81% in the next year. Buy Or Sell Opportunity • Apr 19
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 35% to ₹552. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 16% in a year. Earnings are forecast to grow by 81% in the next year. Price Target Changed • Apr 04
Price target decreased by 15% to ₹350 Down from ₹410, the current price target is an average from 2 analysts. New target price is 15% below last closing price of ₹412. Stock is up 22% over the past year. The company posted a net loss per share of ₹6.16 last year. Aankondiging • Mar 25
An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited (NSEI:SOLARA). An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited (NSEI:SOLARA) on March 25, 2024. Reported Earnings • Feb 16
Third quarter 2024 earnings released: ₹76.49 loss per share (vs ₹0.12 profit in 3Q 2023) Third quarter 2024 results: ₹76.49 loss per share (down from ₹0.12 profit in 3Q 2023). Revenue: ₹2.49b (down 37% from 3Q 2023). Net loss: ₹2.75b (down ₹2.76b from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Aankondiging • Feb 14
Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial Officer Solara Active Pharma Sciences Limited at its meeting held on February 14, 2024 announced that Mr. P.V. Raghavendra Rao resigned as Chief Financial Officer of the Company from the close of business hours on February 15, 2024, due to personal reasons. Aankondiging • Feb 06
Solara Active Pharma Sciences Limited to Report Q3, 2024 Results on Feb 14, 2024 Solara Active Pharma Sciences Limited announced that they will report Q3, 2024 results on Feb 14, 2024 Board Change • Dec 01
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Rajendra Srivastava was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 16
Second quarter 2024 earnings released: ₹4.77 loss per share (vs ₹2.77 loss in 2Q 2023) Second quarter 2024 results: ₹4.77 loss per share (further deteriorated from ₹2.77 loss in 2Q 2023). Revenue: ₹4.26b (up 26% from 2Q 2023). Net loss: ₹171.6m (loss widened 72% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Aankondiging • Oct 20
Solara Active Pharma Sciences Limited Appoints P V Raghavendra Rao as Chief Financial Officer Solara Active Pharma Sciences Limited at its board meeting held on October 19, 2023, approved the appointment of Mr. P V Raghavendra Rao as Chief Financial Officer (CFO) of the Company and designated him as Key Managerial Personnel with effect from October 26, 2023. Mr. P V Raghavendra Rao is a Chartered Accountant from the Institute of Chartered Accountants of India and has close to 23 years of post-qualification work experience. Mr. Rao has a strong track record of handling multiple industries including pharmaceuticals. He comes from Sequent Scientific Limited, where he was the Chief Financial Officer. Before this, he was at Macleods Pharmaceuticals Ltd. and Dr. Reddy's Laboratories Limited, for over 14 years where he handled various roles in finance such as Finance Head Pharmaceutical Services and Active Ingredients, Finance Head FTOs (Formulation Technical Operations), Finance Head Rest of World Markets and Finance Head Integrated Product Development Organization. Prior to Dr. Reddy's he was at New Holland Tractors. Mr. Rao started his career at Indo Asian Fusegear Limited, India, where he worked for 2 years. Price Target Changed • Oct 11
Price target decreased by 9.0% to ₹407 Down from ₹447, the current price target is an average from 3 analysts. New target price is 20% above last closing price of ₹338. Stock is down 19% over the past year. The company is forecast to post earnings per share of ₹18.00 next year compared to a net loss per share of ₹6.16 last year. Recent Insider Transactions • Sep 04
Independent Director recently sold ₹183k worth of stock On the 28th of August, Ramakrishnan Rajagopal sold around 500 shares on-market at roughly ₹366 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹25m more than they bought in the last 12 months. Aankondiging • Aug 22
Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 15, 2023 Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 15, 2023, at 09:30 Indian Standard Time. Agenda: To consider the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2023, together with the Reports of Board of Directors and Auditors thereon; to consider the Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2023, and the Report of Auditors thereon; to consider Board changes; and to consider any other matter thereof. Buying Opportunity • Aug 17
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 1.0%. The fair value is estimated to be ₹457, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.1% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Aug 16
First quarter 2024 earnings released: ₹5.43 loss per share (vs ₹4.56 loss in 1Q 2023) First quarter 2024 results: ₹5.43 loss per share (further deteriorated from ₹4.56 loss in 1Q 2023). Revenue: ₹3.52b (up 6.7% from 1Q 2023). Net loss: ₹195.5m (loss widened 19% from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance. Board Change • Aug 04
High number of new directors There are 5 new directors who have joined the board in the last 3 years. MD, CEO & Director Poorvank Purohit was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Aankondiging • Aug 03
Solara Active Pharma Sciences Limited Announces Executive Changes Solara Active Pharma Sciences Limited announced that Mr. Rajeev Singh has tendered his resignation from the position of Chief Human Resource Officer (CHRO) for better future prospects, the resignation letter is enclosed herewith as Annexure A. As a result, he will cease to be Head of Human Resources (CHRO) with effect from the close of business hours on August 31, 2023. Mr. Pagadala Srinivasan has been appointed as Chief Human Resource Officer(CHRO) with effect from August 1, 2023. He has over 23 years' experience working across reputed pharma companies in India. He joins from Biological E. Ltd. His experience is in handling all gamut of HR. Aankondiging • Jul 06
Solara Active Pharma Sciences Limited Announces Resignation of Jitesh Devendra as A Managing Director and Director Solara Active Pharma Sciences Limited announced the resignation of Mr. Jitesh Devendra (DIN: 06469234) as a Managing Director (MD) and Director and KMP of the company due to pre-occupation. In view of resignation of Mr. Jitesh Devendra (DIN: 06469234) as Managing Director w.e.f. July 5, 2023, the Board of Directors of the Company have also approved the reconstitution of Risk Management Committee and Corporate Social Responsibility Committee. Recent Insider Transactions • Jun 29
MD & Director recently sold ₹5.5m worth of stock On the 23rd of June, Jitesh Devendra sold around 15k shares on-market at roughly ₹369 per share. This transaction amounted to 4.8% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months. Recent Insider Transactions • Jun 13
Independent Director recently sold ₹7.3m worth of stock On the 7th of June, Ramakrishnan Rajagopal sold around 21k shares on-market at roughly ₹354 per share. This transaction amounted to 98% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months. Recent Insider Transactions • May 31
Insider recently sold ₹3.6m worth of stock On the 26th of May, Chaitanya Devendra sold around 10k shares on-market at roughly ₹359 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹3.3m more than they bought in the last 12 months. Recent Insider Transactions • May 21
Insider recently sold ₹1.8m worth of stock On the 17th of May, Sajjan Devendra sold around 5k shares on-market at roughly ₹369 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹306k more than they sold in the last 12 months. Price Target Changed • May 17
Price target decreased by 8.9% to ₹447 Down from ₹491, the current price target is an average from 4 analysts. New target price is 18% above last closing price of ₹378. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₹16.97 next year compared to a net loss per share of ₹6.16 last year. Reported Earnings • May 13
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: ₹6.16 loss per share (improved from ₹16.18 loss in FY 2022). Revenue: ₹14.7b (up 16% from FY 2022). Net loss: ₹221.7m (loss narrowed 62% from FY 2022). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 33%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Aankondiging • May 05
Solara Active Pharma Sciences Limited to Report Q4, 2023 Results on May 12, 2023 Solara Active Pharma Sciences Limited announced that they will report Q4, 2023 results on May 12, 2023 Price Target Changed • Apr 08
Price target decreased by 8.1% to ₹491 Down from ₹534, the current price target is an average from 3 analysts. New target price is 45% above last closing price of ₹339. Stock is down 57% over the past year. The company is forecast to post a net loss per share of ₹10.80 next year compared to a net loss per share of ₹16.18 last year. Aankondiging • Jan 31
USFDA concludes inspection at Solara's Visakhapatnam (Vizag) facility with Zero 483 inspectional observations Solara Active Pharma Sciences Ltd. (Solara) announced that its new state-of-the-art multipurpose API manufacturing facility at Visakhapatnam (Vizag), Andhra Pradesh completed successfully the inspection carried out by the US Food and Drug Administration (US FDA or Agency). The Agency, with its designated investigator, inspected the facility from 23rd to 26th January 2023. The inspection established that the site is in an "Acceptable State of Compliance" with Zero Form 483 inspectional observations from the agency. The Vizag facility of the Company is a green field project spread over 40 acres and has dedicated facilities for manufacturing Ibuprofen API and multipurpose facility in phase 1. The facility has also started validating other APIs to register in various regulated markets across the globe. The site offers a unique capability to the Company for manufacturing various APIs with scale and operational flexibility to achieve a competitive advantage. The site positions Solara as the only Global Company offering Ibuprofen from two USFDA-approved manufacturing sites (Puducherry and Vizag), enhancing supplies for its global partners. Earlier, in November 2022, Solara's Vizag facility had received a Certificate of Suitability (CEP) approval for the manufacture of Ibuprofen API from the European Directorate for the Quality of Medicines (EDQM), the first international regulatory approval for this new facility. Reported Earnings • Jan 26
Third quarter 2023 earnings released: EPS: ₹0.12 (vs ₹38.93 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹0.12 (up from ₹38.93 loss in 3Q 2022). Revenue: ₹4.02b (up 301% from 3Q 2022). Net income: ₹4.50m (up ₹1.40b from 3Q 2022). Profit margin: 0.1% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance. Aankondiging • Jan 26
Solara Active Pharma Sciences Limited Appoints Poorvank Purohit as Chief Executive Officer, Effective from 3 February, 2023 Solara Active Pharma Sciences Limited informed that the Board of Directors of the Company has taken on record/approved the following changes in the Key Managerial Personnel (KMP) at its meeting held on January 25, 2023. The board approved the appointment of Mr. Poorvank Purohit as the Chief Executive Officer. The position of CEO has been vacant since the exit of previous MD & CEO, Mr. Rajender Rao Juvvadi. This appointment is effective from 3rd February, 2023 Mr. Purohit hold a Bachelor in Chemical Engineering from M.S.Ramaiah Institute of Technology, Bangalore. He has also done Executive MBA from IIM Bangalore and completed Advance Management Program from Wharton School. He started his career as Management Trainee with Ranbaxy and progressed through various roles in leading pharma companies Hikel, Alembic, Jubliant Organosys - strong B2B experience in both APIs and Finished Dosage Forms. He is currently the Chief Operating Officer (COO) with R L Fine Chem Pvt Ltd, Bangalore. He has to his credit experience of turning round companies for exponential growth and sustainable organization. His achievement includes building B2B businesses across geographies by establishing strong network and relationship with top Innovator/Generic/Dossier companies including CDMO companies. Holds a strong technical, commercial and management background. Aankondiging • Jan 20
Solara Active Pharma Sciences Limited to Report Q3, 2023 Results on Jan 25, 2023 Solara Active Pharma Sciences Limited announced that they will report Q3, 2023 results at 12:08 PM, Indian Standard Time on Jan 25, 2023 Board Change • Nov 16
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Managing Director Jitesh Devendra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 11
Second quarter 2023 earnings released: ₹2.77 loss per share (vs ₹8.27 profit in 2Q 2022) Second quarter 2023 results: ₹2.77 loss per share (down from ₹8.27 profit in 2Q 2022). Revenue: ₹3.38b (down 16% from 2Q 2022). Net loss: ₹99.6m (down 134% from profit in 2Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance. Buying Opportunity • Oct 31
Now 21% undervalued Over the last 90 days, the stock is up 1.3%. The fair value is estimated to be ₹501, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year. Buying Opportunity • Oct 07
Now 20% undervalued Over the last 90 days, the stock is up 14%. The fair value is estimated to be ₹547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year. Buying Opportunity • Sep 16
Now 20% undervalued Over the last 90 days, the stock is up 22%. The fair value is estimated to be ₹537, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year. Recent Insider Transactions • Sep 03
Insider recently bought ₹390k worth of stock On the 29th of August, Shankarlal Devendra bought around 900 shares on-market at roughly ₹433 per share. This transaction increased Shankarlal Devendra's direct individual holding by 9x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹1.3m. Insiders have collectively bought ₹117m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Aug 26
Insider recently bought ₹1.3m worth of stock On the 19th of August, Pooja Srisrimal bought around 3k shares on-market at roughly ₹435 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹124m more in shares than they have sold in the last 12 months. Buying Opportunity • Aug 19
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be ₹544, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year. Reported Earnings • Aug 03
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: ₹16.18 loss per share (down from ₹69.00 profit in FY 2021). Revenue: ₹12.7b (down 22% from FY 2021). Net loss: ₹581.5m (down 126% from profit in FY 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 25%, compared to a 13% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.